Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1 Trials
Two phase 3 randomized, placebo-controlled trials (First Light and Radiant Light) evaluated the oral orexin receptor 2-selective agonist oveporexton in participants aged 16 to 70 with narcolepsy type 1 over 12 weeks. The trials reported significantly greater improvements with oveporexton versus placebo in sleep latency, Epworth Sleepiness Scale scores, and weekly cataplexy rate (all P<0.001), though adverse events, most commonly increased urinary frequency and transient insomnia, occurred in 86 to 89% of oveporexton recipients compared with 43 to 54% on placebo.
Most relevant for: Patients aged 16 to 70 with narcolepsy type 1 experiencing excessive daytime sleepiness and cataplexy.
Read the original at New England Journal of MedicineSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More psychiatry updates
- Caring Letters Not Linked to Lower Suicide Mortality in VeteransOct 14, 2026
- US benzodiazepine dispensing fell 26.7% from 2013 to 2024Sep 30, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 1 mL, Delivers: 10 mL, Oral Elixir, PAI, Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 10 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 10 mg per 2 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026